Furthermore, the inhibitor ISOX, by targeting the deacetylase HDAC6, promotes non-histone acetylation modifications of the proto-oncogene c-Myc, leading to reduced c-Myc protein stability and thereby inhibiting pancreatic cancer stem cell properties, tumour growth, and metastasis [172]. This evidence concerns the gene MYC and familial pancreatic carcinoma.